Hepatic Glycogen Storage Diseases: Pathogenesis, Clinical Symptoms and Therapeutic Management
Total Page:16
File Type:pdf, Size:1020Kb
State of the art paper Hepatology Hepatic glycogen storage diseases: pathogenesis, clinical symptoms and therapeutic management Edyta Szymańska1, Dominika A. Jóźwiak-Dzięcielewska2, Joanna Gronek2, Marta Niewczas3, Wojciech Czarny4, Dariusz Rokicki1, Piotr Gronek2 1Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Corresponding author: The Children’s Memorial Health Institute, Warsaw, Poland Edyta Szymańska MD, PhD 2Laboratory of Genetics, Department of Gymnastics and Dance, University School Department of Physical Education, Poznan, Poland of Gastroenterology, 3Department of Sport, Faculty of Physical Education, University of Rzeszow, Rzeszow, Hepatology, Feeding Poland Disorders and 4Department of Human Sciences, Faculty of Physical Education, University of Rzeszow, Pediatrics Rzeszow, Poland The Children’s Memorial Health Institute Submitted: 13 October 2017; Accepted: 8 December 2017; Al. Dzieci Polskich 20 Online publication: 18 February 2019 Warsaw, Poland Phone: +48 22 815 74 94 Arch Med Sci 2021; 17 (2): 304–313 E-mail: edyta.szymanska@ DOI: https://doi.org/10.5114/aoms.2019.83063 ipczd.pl Copyright © 2019 Termedia & Banach Abstract Glycogen storage diseases (GSDs) are genetically determined metabolic diseases that cause disorders of glycogen metabolism in the body. Due to the enzymatic defect at some stage of glycogenolysis/glycogenesis, excess glycogen or its pathologic forms are stored in the body tissues. The first symptoms of the disease usually appear during the first months of life and are thus the domain of pediatricians. Due to the fairly wide access of the authors to unpublished materials and research, as well as direct contact with the GSD patients, the article addresses the problem of actual diag- nostic procedures for patients with the suspected diseases. Knowledge and awareness of the problem among physicians seem insufficient, and research on the diagnosis and treatment of GSD is still ongoing, resulting in a hetero- geneous GSD typology and a changing way of its diagnosis and treatment. Key words: glycogen storage disease, hypoglycemia, hepatomegaly. Introduction Glycogen is a complex/polymeric physiological glucose carbohydrate found mainly in the liver but also in skeletal muscles, kidneys and entero- cytes. Its role is to store glucose, which is used as an endogenous source of energy following enzymatic digestion (glycogenolysis process) within 3–4 h after the meal in order to maintain normoglycemia. Glycogen is, therefore, a source of glucose obtained from hepatocytes during a short period of fasting or used for the needs of skeletal muscles in the first early phase of myocytes [1]. Glucose deficiency in the central nervous system (CNS) can lead to neuroglycopenia [2]. There might be symp- toms similar to hypoxia, convulsions, irritability and cognitive decline. Permanent and prolonged hypoglycemia may lead to permanent CNS damage [3]. Systemic hypoglycemia is characterized by signs of sympa- thetic stimulation/activation, including tachycardia, excessive sweating, fatigue, muscle weakness, irritability, anger, hunger, seizures, headaches and dizziness [4]. Creative Commons licenses: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY -NC -SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/). Hepatic glycogen storage diseases: pathogenesis, clinical symptoms and therapeutic management Under physiological conditions, the liver plays below the critical lower limit (long after food intake a key role in the metabolism of consumed carbo- or effort), the body is ready for a certain compen- hydrates by storing them in the form of glycogen, sation and attempts to derive it from non-sugar thereby preventing postprandial hyperglycemia precursors (for example alanine), but some pro- [5]. Synthesis of glycogen consists in combining cesses cannot be replaced or stopped [10]. An ex- glucose monomers with glycogen protein and ample is metabolic acidosis with increased blood α1,4- or α1,6-glycosidic bonds [6]. This process lactate level with no characteristic symptoms. It can be quickly reversed when the energy require- is associated with accumulation of lactic acid in ments in the body cells rise again, and the blood cells above 5 mmol/l [11]. This condition results glucose levels fall (Figure 1). from acid-base balance disorders, and the symp- Glycogen itself is a branched glucose polymer toms are weakness, nausea, vomiting, diarrhea, that is osmotically passive [7]. Due to the activity and abdominal pain [11]. The glucose metabolism of many enzymes, hormone regulation and proper pathway in the body can be modulated by using, conditions in the cell, a healthy body “regulates” among other things, a diet rich in complex carbo- and “adjusts” glucose metabolism processes, hydrates [12]. sometimes “giving warning signals” when it is no In this manuscript, the authors discuss GSDs in longer able to use its own energy resources [3]. general in the first part of the paper, and then, lat- Irregularities in the above-mentioned metabolic er in the text, they focus only on the hepatic types. processes cause problems for the basic function- ing of the body [8]. Changes related to the disor- Glycogen storage diseases (glycogenoses) der of glycogen metabolism are characterized by Pathophysiology and epidemiology symptoms varying from developmental delay, es- pecially of motor functions, to serious and imme- Glycogen storage disease (GSD) is caused by diate neuroglycopathy, which is a life-threatening a genetically determined metabolic block involv- condition. In addition, as a result of the accumu- ing enzymes that regulate synthesis (glycogene- lation of abnormal glycogen molecules, fatty liver sis) or glycogen breakdown (glycogenolysis) [13]. occurs, and in extreme cases the storage of abnor- The nature of the individual types of glycogenosis mal glycogen forms lead to fibrosis and cirrhosis is related to the impaired accumulation of abnor- (GSD type IV) [9]. mal molecules of this branched polysaccharide To keep blood glucose levels within a narrow [14]. Moreover, GSD, although it is not a seman- range (70–140 mg/dl) around the clock, hepatic tically correct name, also refers to a deficit in gly- absorption of postprandial glucose is counterbal- cogen synthase (the so-called type 0 GSD), which anced by its “peripheral” (through other organs) consists in the lack of glycogen in tissues due to consumption. When the blood glucose level drops the inability to polymerize glucose molecules (lack Adenylate cyclase GTP GDP α g β ATP Cyclic AMP Protein Protein kinase A kinase A Phosphorylase Phosphorylase kinase kinase Phosphorylase b Phosphorylase a Figure 1. Cascade of glycogen breakdown Arch Med Sci 2, February / 2021 305 Edyta Szymańska, Dominika A. Jóźwiak-Dzięcielewska, Joanna Gronek, Marta Niewczas, Wojciech Czarny, Dariusz Rokicki, Piotr Gronek of enzyme catalyzing the glycogen synthesis reac- Özen [17] classifies GSDs on the basis of the tion) [15]. latest knowledge in the field, their enzymatic In the International Statistical Classification of deficits or involved tissues, mainly on the basis Diseases and Related Health Problems (ICD-10), of available case studies. Case studies and data glycogenosis is placed under the symbol E74.0 collection during patient health monitoring prove [icd10.pl]. an increase in the number of GSDs studies [18, Most genetically determined diseases are rare 22, 23]. The knowledge and awareness of these [16]. These are chronic conditions, usually pro- complex metabolic pathologies are increasing. The gressive and mostly severe. The prevalence of author divided the aforementioned disorders into metabolic blocks associated with glycogen is esti- hepatic, mixed, and muscular GSDs (Table II) [17]. mated at 1 : 25,000 (40,000) births [17]. The typical, biochemical characteristics of Clinical symptoms this type of GSD are postprandial hyperglycemia The basic clinical symptoms common for every (blood glucose cannot be stored in the liver and type of hepatic GSD are hypoglycemia and hep- therefore it is kept high in the blood) with subse- atomegaly [24]. A characteristic feature for muscle quent hypoglycemia (no hepatic glycogen storage GSDs is progressive muscle pathology, including from which the body could ‘boost’ the reserves in exercise-induced muscle weakness [25]. Metabolic case of a drop in the blood glucose). acidosis with hypercholesterolemia and hyperlipid- Individuals affected by glycogenosis in Poland emia are found in blood biochemistry [26]. In both may apply for a disability ruling due to the disor- types of GSDs, there is also hypertransaminasemia der which, irrespective of the source of its occur- (elevated activity of liver enzymes – aminotrans- rence, causes disorder of the body functionality or ferases). Physical development delay, mostly in the limitation in performing life and social activities. form of short stature or motor latency, is a typical clinical symptom. GSDs are a group of heteroge- Inheritance neous genetic diseases; therefore each type has its Glycogen storage diseases, like most metabolic distinct, specific clinical presentation [27]. diseases, are inherited in an autosomal recessive (AR) way. These are the innate defects of carbohy- Diagnosis drate metabolism that affect the liver, muscles or The diagnosis of GSD is based on clinical signs both of these organs (the so-called mixed types) and/or symptoms related to hypoglycemia